About Us

Specialists in the newest nutraceuticals.

Our history

Koncare Biotech was born in 2019 with the aim of leading the care and improving the quality of life of our patients.

All this, through the development of natural products endorsed under strict quality standards, both by our internal controls and by regulatory authorities natural products endorsed under strict quality standards, both by our internal controls and by regulatory authorities.

Investigation

We research and develop products aimed at the treatment of microbiota.

Expansion

We set up a commercial network that provides services to the entire Spanish territory.

Globalization

We are working on partnership agreements to enter the European market.

Our mission

Koncare aims to improve Life quality of our patients.

To this end, we develop comprehensive solutions for pathologies such as SIBO, IBS, Dyspepsia, Hepatic Steatosis and Cholesterol, Chronic Constipation and Helicobacter Pylori.

Our vision

We want to be leaders in our Therapeutic areas thanks to our innovative treatments.

This is why we make our products available to healthcare professionals, offering them the most complete formulations for patients.

Our experts

Dr. Michel Blé

Our medical director, Dr. Michel Blé, is a specialist in Digestive System by the La Fe University and Polytechnic Hospital in Valencia.
In addition, he has a Master’s Degree in Clinical Research at the specialty of Liver Diseases from the University of Barcelona and is a member of the European Society of Gastroenterology and Hepatology.

Dr. José Altamirano

He received his training in Internal Medicine at the Dr. Manuel Gea González General Hospital and his training in Digestive-Gastroenterology at the Juárez Hospital in Mexico City, focusing his interest in hepatology and metabolic medicine .

Throughout his career he has combined his healthcare work with important research and dissemination activity, being the author of more than 60 scientific articles on Hepatology, Liver Transplantation and Gastroenterology. He is also a regular speaker at conferences in the specialty and his teaching work is carried out as a professor of the hepatology module of the Master of Digestive System at the Open University of Catalonia.

He currently carries out his clinical activity aimed at the diagnosis and treatment of liver and digestive diseases as an attending physician at the Quirónsalud Hospital, Barcelona, Dexeus-Quiron University Hospital, Barcelona and in the Metabolism Unit in Corachan Clinic, Barcelona.

Nutraceuticals

The term “nutraceutical” is used to refer to any nutritment or food derivative with additional health benefits to its nutritional value.

They are generated through biotechnological processes, after the isolation and purification of nutrients and/or bioactive substances. From them we can expect to stimulate general well-being, prevent and control the symptoms of diseases, delay aging and increase life expectancy, as well as support the functions and the body integrity.

Nutraceuticals comply with the following principles:

They are products of natural origin
Isolated and purified by non-denaturing methods
Provide beneficial health effects
Stability and toxicology tested
With clinical studies
R&D according to state-of-the-art methods

This term encompasses natural products from herbs and derivatives to pure foods, isolated nutrients, dietary supplements and specific diets:

FUNCTIONAL (FOOD)

MEDICINAL (FOOD)

DIETARY SUPPLEMENTS

Commitment to R&D&i

This constant challenge leads us to continue investigating.

The close collaboration with the most prominent companies in the sector allows us to be at the forefront of R&D&i, being able to offer the latest scientific advances.

PRIMARY PREVENTION

in Cardiovascular Pathology

In 2020, we developed COLESYN in collaboration with ROELMI HPC, a global expert in health and personal care innovation.
COLESYN is a benchmark in the treatment of hypercholesterolaemia, reducing the adverse effects of current treatments and ensuring greater efficacy and safety.

THE MICROBIOTA

In treatment of pathologies Digestive

During 2021, we reached agreements for the research and manufacturing of products targeting the microbiota.
As a result, we developed SIBOK, for thetreatment of overexpression of this bacterial growth.

ENTERING THE INTERNATIONAL MARKET

We enter the European Union

We are becoming a pioneering company in the sector and we feel to guarantee the continuous improvement in life quality of our patients around the world.
Therefore, during 2024 we will proceed with our international expansion, establishing collaborations with different European partners.

All of this is possible thanks to our researchers and the excellent human capital that makes up Koncare Biotech, of which we are very proud, but above all our great pride is in helping our patients.

Helping you.

Benefited Patients

LEARN MORE ABOUT OUR PRODUCTS